WO2019168791A3 - Single-chain il-2/antibody fusions that selectively activate regulatory t cells - Google Patents

Single-chain il-2/antibody fusions that selectively activate regulatory t cells Download PDF

Info

Publication number
WO2019168791A3
WO2019168791A3 PCT/US2019/019421 US2019019421W WO2019168791A3 WO 2019168791 A3 WO2019168791 A3 WO 2019168791A3 US 2019019421 W US2019019421 W US 2019019421W WO 2019168791 A3 WO2019168791 A3 WO 2019168791A3
Authority
WO
WIPO (PCT)
Prior art keywords
chain
cells
selectively activate
antibody fusions
activate regulatory
Prior art date
Application number
PCT/US2019/019421
Other languages
French (fr)
Other versions
WO2019168791A2 (en
Inventor
Kenan Christopher GARCIA
Jamie SPANGLER
Jeffrey A. Bluestone
Eleanora TROTTA
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University, The Regents Of The University Of California filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2019168791A2 publication Critical patent/WO2019168791A2/en
Publication of WO2019168791A3 publication Critical patent/WO2019168791A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Antibody-IL-2 single-chain fusions (immunocytokines) with selective activity in expansion of T cell subsets are provided herein. Methods of use include administering an agent of the invention to expand particular immune cell subpopulations as a research tool or to treat disease or disease models through induction of selective IL-2 activity.
PCT/US2019/019421 2018-02-28 2019-02-25 Single-chain il-2/antibody fusions that selectively activate regulatory t cells WO2019168791A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636605P 2018-02-28 2018-02-28
US62/636,605 2018-02-28

Publications (2)

Publication Number Publication Date
WO2019168791A2 WO2019168791A2 (en) 2019-09-06
WO2019168791A3 true WO2019168791A3 (en) 2019-11-21

Family

ID=67805886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/019421 WO2019168791A2 (en) 2018-02-28 2019-02-25 Single-chain il-2/antibody fusions that selectively activate regulatory t cells

Country Status (1)

Country Link
WO (1) WO2019168791A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510115A (en) 2019-12-20 2023-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド NOVEL IL2 AGONISTS AND METHODS OF USING THEM
KR102627471B1 (en) * 2020-02-16 2024-01-18 아울로스 바이오사이언스 인코포레이티드 Engineered anti-IL-2 antibodies
MX2022010218A (en) * 2020-02-21 2022-09-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106369A1 (en) * 2000-03-17 2002-08-08 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
US20090098609A1 (en) * 2001-12-04 2009-04-16 Merck Patent Gmbh Il-2 fusion proteins with modulated selectivity
US20110059097A1 (en) * 2008-02-22 2011-03-10 University Health Network MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells
WO2017122130A1 (en) * 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106369A1 (en) * 2000-03-17 2002-08-08 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
US20090098609A1 (en) * 2001-12-04 2009-04-16 Merck Patent Gmbh Il-2 fusion proteins with modulated selectivity
US20110059097A1 (en) * 2008-02-22 2011-03-10 University Health Network MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells
WO2017122130A1 (en) * 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof

Also Published As

Publication number Publication date
WO2019168791A2 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
SG11201906780SA (en) Bcma-targeting antibody and use thereof
WO2019168791A3 (en) Single-chain il-2/antibody fusions that selectively activate regulatory t cells
SG11201900171QA (en) Antibody for anti-claudin 18a2 and use thereof
WO2017201432A3 (en) Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CA3010621A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MX2021000083A (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases.
PE20191812A1 (en) COMPOUNDS AND METHODS FOR SPECIFIC CELL TUMOR REDUCTION
JOP20200020B1 (en) Interleukin-21 muteins and methods of treatment
MX2021006786A (en) Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof.
SA518390903B1 (en) Novel anti-PD-1 antibodies
SA518390862B1 (en) Anti - pd - l1 antibodies
TWD199477S (en) Solar cell
EP4317180A3 (en) Trifunctional t cell-antigen coupler and methods and uses thereof
WO2017066136A3 (en) Antibody agents specific for human cd19 and uses thereof
SA517390134B1 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
MX2019000641A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use.
PH12018501902A1 (en) Gitr antibodies, methods, and uses
WO2018064255A3 (en) Antibodies that bind interleukin-2 and uses thereof
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
NZ730124A (en) A method of predicting risk of recurrence of cancer
PH12017501856A1 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
AU2017242811A1 (en) Marine vessel
NL7414916A (en) METHOD AND EQUIPMENT FOR REGULATING THE PROPULSION OF VESSELS, AS WELL AS VESSELS WITH SUCH EQUIPMENT.
NL143176B (en) IMPROVEMENT OF THE METHOD FOR PREPARING A LACQUER FOR PRINTING PLATES AND PRINTING PLATES, MADE WITH A LACQUER PREPARED IN THIS WAY.
NL173032C (en) SHOOTING TOOL, PARTICULARLY FOR SHOOTING BOLTS.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19761081

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19761081

Country of ref document: EP

Kind code of ref document: A2